GlassScriptPhysician profile
Emily Garritson
NPI 1659637791
$12,075.26
in general payments reported to CMS, 2019-2025
36 companies · $2,298 in 2025
The $2,298 reported for 2025 was more than what 79% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,816 · 2020: $1,294 · 2021: $1,601 · 2022: $1,666 · 2023: $1,622 · 2024: $1,779 · 2025: $2,298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,316 · Education: $383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,316.11 |
| Education | $382.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,000.53 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,408.89 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,204.81 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $1,052.06 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Lilly USA, LLC | $866.97 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $755.18 | 2019-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $699.42 | 2019-2025 | |
| Ucb, INC. | $570.09 | 2019-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $471.62 | 2019-2025 | Winlevi, Ilumya |
| Incyte Corporation | $354.02 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $344.48 | 2019-2021 | |
| Amgen INC. | $263.25 | 2019-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $249.53 | 2019-2025 | Jublia, Cabtreo, Siliq |
| Dermavant Sciences, INC. | $230.01 | 2023-2024 | Vtama |
| Biofrontera INC. | $195.14 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $175.99 | 2022-2024 | Sotyktu |
| Vyne Pharmaceuticals INC. | $171.89 | 2020-2021 | |
| Celgene Corporation | $130.43 | 2019-2022 | |
| Pfizer INC. | $126.82 | 2019-2021 | |
| Organon LLC | $126.51 | 2025 | Vtama, Hadlima, Nexplanon |
| Janssen Scientific Affairs, LLC | $125.00 | 2021 | |
| Mayne Pharma Commercial LLC | $107.42 | 2019-2025 | |
| Kerecis Limited | $89.52 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Epi Health, LLC | $65.33 | 2021 | |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $39.28 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.11 | 2025 | Spevigo |
| Arcutis Biotherapeutics, INC. | $31.98 | 2023-2025 | Zoryve |
| Mission Pharmacal Company | $27.92 | 2019 | |
| Encore Dermatology INC. | $26.79 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $24.68 | 2019 | |
| Almirall LLC | $24.24 | 2021 | |
| Mylan Pharmaceuticals INC. | $21.57 | 2019 | |
| Prugen, INC. Pharmaceuticals | $18.25 | 2019 | |
| Aclaris Therapeutics, INC. | $16.95 | 2019 | |
| Dermira, INC. | $13.54 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Garritson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.